BD Acquires MedKeeper to Offer Cloud-Based Connected Pharmacy Software

Acquisition contributes to the company’s recent growth in high-tech pharmacy solutions and accelerates the company’s commitment to Smart, Connected Care – by providing a customizable platform to optimize IV workflow

FRANKLIN LAKES, NJ, July 28, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications.

MedKeeper strategically complements BD’s existing pharmacy presence, where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization.

MedKeeper’s platform will become part of the company’s existing portfolio of connected medication management capabilities. Combining MedKeeper’s platform with BD’s broad technological expertise, the companies will work to optimize compound drug compounding – a critical need in today’s pharmacy.

“Preparing the right dose for patients requires a combination of factors, including staffing, training and compliance. Pharmacists leaders need IV workflow management technology that is tailored to their needs and works within their environment,” said Mike Garrison, global president of drug management solutions at BD. “Adding MedKeeper to our portfolio will allow us to provide our customers with easy-to-use, customizable solutions that make meaningful and incremental progress in IV workflow management.”

Today, many pharmacies use a combination of both manual and technical tools for their IV workflow management system. Adding MedKeeper to BD’s Medication Management Solutions portfolio will further enhance the company’s ability to deliver solutions that best meet customer needs – now and in the future.

“The demands of today’s pharmacy environment, such as COVID-affected labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacist software solutions to support flexible, focused workflow, inventory tracking and reporting needs in sterile and non-sterile compounding.” said Garrison. “Manual, time-consuming procedures that were once ‘good enough’ can now be replaced and augmented with software that enables pharmacists to provide a higher standard of care.”

Story continues

BD and MedKeeper will work to provide customers with flexibility and opportunities to meet industry standards for compounding drug compounding, incorporating the latest regulatory guidelines. Together, the companies are committed to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiency to their frontline clinicians.

The transaction is not expected to be material to BD’s financial results in 2022.

About BD
BD is one of the largest global medical technology companies in the world and is moving the world of health forward™ by improving medical discovery, diagnostics and care delivery. The company supports the heroes on the frontline of healthcare by developing innovative technology, services and solutions that advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 70,000 associates have a passion and commitment to help improve the safety and efficiency of clinicians’ care delivery processes, enable laboratory scientists to accurately detect disease, and enhance researchers’ capabilities to develop the next generation of diagnostic and therapeutic agents . BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working closely with customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information about BD, visit: bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

FORWARD-LOOKING STATEMENTS
This press release contains certain estimates and other forward-looking statements (as defined in the federal securities laws) regarding the expected benefits of the MedKeeper acquisition. Forward-looking statements are generally accompanied by words such as “will”, “expect”, or similar words, phrases or expressions. These statements are based on management’s current expectations and are subject to a number of risks and uncertainties relating to MedKeeper’s business and the acquisition, and actual results could differ materially from those anticipated in any forward-looking statement. described, implied or projected. These risks and uncertainties include, but are not limited to, risks related to the integration of MedKeeper’s technology, software and employees into BD and the time and resources required to do so and the possibility that the expected benefits of the acquisition will not be completed or will not be completed within the expected timeframe; competitive factors, including the development of new technologies by other companies and pressure on pricing and market share; changes in healthcare or other government regulations; risks related to the ability to maintain favorable supplier agreements and relationships; changes in regional, national or foreign economic conditions, as well as other factors discussed in BD’s filings with the Securities Exchange Commission. BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.

View original content to download multimedia: https://www.prnewswire.com/news-releases/bd-acquires-medkeeper-to-offer-cloud-based-connected-pharmacy-software-301594770.html

SOURCE BD (Becton, Dickinson and Company)